tbuckley/cabot-search huggingface dataset:
786P A phase II trial of paclitaxel, ifosfamid and cisplatin in patients with poor-prognosis disseminated non-seminomatous germ cell tumors with unfavorable serum tumor marker decline after first cycle of chemotherapy
Authors: M. Mego, D. Svetlovska, K. Rejlekova, V. Miskovska, V. De Angelis, K. Kalavska, J. Obertova, P. Palacka, Z. Sycova-Mila, M. Chovanec, J. Mardiak
Journal: Annals of Oncology (2020)
688TiP Genetic information to inform treatment and screening (GIFTS) study for prostate cancer: Characterizing germline DNA alterations in men with metastatic prostate cancer and their first-degree male relatives
Authors: R.L. Wong, D.W. Lin, C.C. Pritchard, P.S. Nelson, J.L. Stanford, H.H. Cheng
Journal: Annals of Oncology (2020)
A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD
Authors: Pei Yee Tiew, Alison J. Dicker, Holly R. Keir, Mau Ern Poh, Sze Lei Pang, Micheál Mac Aogáin, Branden Qi Yu Chua, Jiunn Liang Tan, Huiying Xu, Mariko Siyue Koh, Augustine Tee, John Arputhan Abisheganaden, Fook Tim Chew, Bruce E. Miller, Ruth Tal-Singer, James D. Chalmers, Sanjay H. Chotirmall
Journal: European Respiratory Journal (2020)

The chronic obstructive pulmonary disease (COPD) bacteriome associates with disease severity, exacerbations and mortality. While COPD patients are susceptible to fungal sensitisation, the role of the fungal mycobiome remains uncertain.We report the largest multicentre evaluation of the COPD airway mycobiome to date, including participants from Asia (Singapore and Malaysia) and the UK (Scotland) when stable (n=337) and during exacerbations (n=66) as well as nondiseased (healthy) controls (n=47). Longitudinal mycobiome analysis was performed during and following COPD exacerbations (n=34), and examined in terms of exacerbation frequency, 2-year mortality and occurrence of serum specific IgE (sIgE) against selected fungi.A distinct mycobiome profile is observed in COPD compared with controls as evidenced by increased α-diversity (Shannon index; p<0.001). Significant airway mycobiome differences, including greater interfungal interaction (by co-occurrence), characterise very frequent COPD exacerbators (three or more exacerbations per year) (permutational multivariate ANOVA; adjusted p<0.001). Longitudinal analyses during exacerbations and following treatment with antibiotics and corticosteroids did not reveal any significant change in airway mycobiome profile. Unsupervised clustering resulted in two clinically distinct COPD groups: one with increased symptoms (COPD Assessment Test score) and Saccharomyces dominance, and another with very frequent exacerbations and higher mortality characterised by Aspergillus, Curvularia and Penicillium with a concomitant increase in serum sIgE levels against the same fungi. During acute exacerbations of COPD, lower fungal diversity associates with higher 2-year mortality.The airway mycobiome in COPD is characterised by specific fungal genera associated with exacerbations and increased mortality.
Three-dimensional bio-printing of primary human hepatocellular carcinoma for personalized medicine
Authors: Feihu Xie, Lejia Sun, Yuan Pang, Gang Xu, Bao Jin, Haifeng Xu, Xin Lu, Yiyao Xu, Shunda Du, Yanan Wang, Shi Feng, Xinting Sang, Shouxian Zhong, Xin Wang, Wei Sun, Haitao Zhao, Hongbing Zhang, Huayu Yang, Pengyu Huang, Yilei Mao
Journal: Biomaterials (2020)
A stepped-wedge randomized trial and qualitative survey of HIV pre-exposure prophylaxis uptake in the Eswatini population
Authors: Pascal Geldsetzer, Kate Bärnighausen, Anita Hettema, Shannon A. McMahon, Shona Dalal, Rachel P. Chase, Catherine E. Oldenburg, Stefan Kohler, Simiao Chen, Phiwayinkhosi Dlamini, Mxolisi Mavuso, Allison B. Hughey, Sindy Matse, Till Bärnighausen
Journal: Science Translational Medicine (2020)

Promoting HIV pre-exposure prophylaxis at primary care clinics in Eswatini led to an increase in uptake among at-risk adults.
337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study
Authors: F. Nichetti, A. Marra, C.A. Giorgi, G. Randon, S. Scagnoli, C. De Angelis, C. Molinelli, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, C.G. Rea, D. Basile, L. Gerratana, M. Cinausero, C. Vernieri
Journal: Annals of Oncology (2020)
Bone Regeneration: A Multi‐Functional Implant Induces Bone Formation in a Diabetic Model (Adv. Healthcare Mater. 18/2020)
Authors: Behnoush Khorsand, Timothy M. Acri, Anh‐Vu Do, John E. Femino, Emily Petersen, Douglas C. Fredericks, Aliasger K. Salem
Journal: Advanced Healthcare Materials (2020)

In article number 2000770 by Aliasger K. Salem and co-workers, the local delivery of insulin, Vitamin D3 metabolites, and BMP-2 and FGF-2 genes from a collagen scaffold is investigated to promote bone formation in Type-2 diabetic rats. The ectopic formation of bone in diabetic rats suggests this approach has strong potential for bone regeneration in diabetic patients.
1852P Chronic cannabis used by patients with advanced cancer during Immunotherapy initiation: clinical outcomes and endocannabinoid levels evaluation
Authors: G. Bar-Sela, I. Choen, S. Campisi-Pinto, G. Lewitus, L. Oz-Ari, A. Jehassi, A. Peer, I. Turgeman, O. Vernicova, P. Berman, M. Wollner, M. Moskovitz, D. Meiri
Journal: Annals of Oncology (2020)
925P Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)
Authors: A. Vienne, L. Collet, T. Chevalier, C. Borel, M.P. Tardy, F. Huguet, S. Richard, S. Salas, E. Saada-Bouzid, J. Fayette, A. Daste
Journal: Annals of Oncology (2020)
812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
Authors: N. Colombo, J. Gantzer, B. Ataseven, C. Cropet, G. Scambia, A. Herrero, P. Sevelda, H. Kobayashi, P. Vuylsteke, M.R. Mirza, F. Priou, P. Buderath, C. Pisano, N. Lainez, C. Guillemet, A. Burges, R. Sverdlin, A. El-Balat, N. Raban, I.L. Ray-Coquard
Journal: Annals of Oncology (2020)
637P The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial
Authors: A. Meisel, C. Parker, R. Kühne, O. Sartor, F. Stenner-Liewen
Journal: Annals of Oncology (2020)
609O Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
Authors: B. Tran, L. Horvath, T. Dorff, M. Rettig, M.P. Lolkema, J-P. Machiels, S. Rottey, K. Autio, R. Greil, N. Adra, C. Lemech, M. Minocha, F-C. Cheng, H. Kouros-Mehr, K. Fizazi
Journal: Annals of Oncology (2020)
959P Analysis of concurrent chemo-radiation using weekly cisplatin in locally advanced SCCHN: Identification of prognostic factors
Authors: A. Sharma, B.K. Mohanti, A. Thakar, S. Bhasker, K. Sikka, A.C. Singh, R. Pramanik, R. Kumar, A. Biswas, S. Deo, S. Thulkar, S. Bahadur
Journal: Annals of Oncology (2020)
1581O Estimation of European cancer burden for the year 2020
Authors: T.A. Dyba, G. Randi, M.D.C. Martos, F. Giusti, J. Ferlay, F. Bray, N. Dimitrova, L. Neamtiu, N. Nicholson, R. Carvalho, M. Bettio
Journal: Annals of Oncology (2020)
Successful return to professional men’s football (soccer) competition after the COVID-19 shutdown: a cohort study in the German Bundesliga
Authors: Tim Meyer, Dietrich Mack, Katrin Donde, Oliver Harzer, Werner Krutsch, Annika Rössler, Janine Kimpel, Dorothee von Laer, Barbara C Gärtner
Journal: British Journal of Sports Medicine (2020)

Objectives To evaluate the restart of the German Bundesliga (football (soccer)) during the COVID-19 pandemic from a medical perspective. Methods Participants were male professional football players from the two highest German leagues and the officials working closely with them. Our report covers nine match days spread over 9 weeks (May to July 2020). Daily symptom monitoring, PCR testing for SARS-CoV-2 RNA twice weekly, and antibody tests (on two occasions—early during the phase in May 2020 and in the week of the last match) were conducted. Target variables were: (1) onset of typical COVID-19 symptoms, (2) positive PCR results, and (3) IgG seroconversion against SARS-CoV-2. All detected seroconversions were controlled by neutralisation tests. Findings Suspicious symptoms were reported for one player; an immediate additional PCR test as well as all subsequent diagnostic and antibody tests proved negative for coronavirus. Of 1702 regularly tested individuals (1079 players, 623 officials members), 8 players and 4 officials tested positive during one of the first rounds of PCR testing prior to the onset of team training, 2 players during the third round. No further positive results occurred during the remainder of the season. 694 players and 291 officials provided two serum samples for antibody testing. Nine players converted from negative/borderline to positive (without symptoms); two players who initially tested positive tested negative at the end of the season. 22 players remained seropositive throughout the season. None of the seroconversions was confirmed in the neutralisation test. Conclusion Professional football training and matches can be carried out safely during the COVID-19 pandemic. This requires strict hygiene measures including regular PCR testing.
1039P Analysis of predictive and prognostic soluble biomarkers in advanced non-small cell lung cancer (NSCLC) patients treated with anti-PD1/PDL1
Authors: S. Gallach Garcia, J. Garde Noguera, S. Torres Martinez, F.D.A. Aparisi Aparisi, J. Vidal Martínez, E. Escorihuela, R. Gisbert Criado, A. Moreno, M. Ferrero Gimeno, M. Meri Abad, I. Shaheen, S. Calabuig-Fariñas, A. Blasco Cordellat, B. Honrubia Peris, J. García Sánchez, E. Jantus Lewintre, C. Camps
Journal: Annals of Oncology (2020)
CN38 Implementing a nursing symptom self-management intervention: The Symptom Navi Program
Authors: M. Bana, K. Ribi, S. Kropf-Staub, S. Zürcher-Florin, E. Näf, C. Bläuer, M. Borner, N. Cantoni, T. Seeger, D. Betticher, L. Bütikofer, S. Peters, M. Eicher
Journal: Annals of Oncology (2020)
Bottom‐up Tissue Engineering: TGase‐Enhanced Microtissue Assembly in 3D‐Printed‐Template‐Scaffold (3D‐MAPS) for Large Tissue Defect Reparation (Adv. Healthcare Mater. 18/2020)
Authors: Hongsheng Yu, Zhifeng You, Xiaojun Yan, Wei Liu, Zhirui Nan, Dan Xing, Chenyu Huang, Yanan Du
Journal: Advanced Healthcare Materials (2020)
Bioactive antiinflammatory antibacterial hemostatic citrate-based dressing with macrophage polarization regulation for accelerating wound healing and hair follicle neogenesis
Authors: Wenguang Liu, Min Wang, Wei Cheng, Wen Niu, Mi Chen, Meng Luo, Chenxi Xie, Tongtong Leng, Long Zhang, Bo Lei
Journal: Bioactive Materials (2020)

The efficient cutaneous wound healing accompanied with the enhanced skin appendage regeneration is still a challenge. The bacterial infection and excessive/prolonged inflammation inhibit wound healing process and result in the scar formation. Herein, we reported an anti-inflammatory polycitrate-polyethyleneimine-Ibuprofen (PCEI) and multifunctional PCEI-based F127-ε-polypeptide-alginic (FEA) dressing (FEA-PCEI) for accelerating wound healing and hair follicle neogenesis. PCEI showed the excellent anti-inflammation function through stimulating macrophage towards anti-inflammatory M2 subtype polarization. The FEA-PCEI dressing showed the temperature-response gelation, injectability, robust antibacterial activity, light-damage-resistant, homeostasis ability, and good cytocompatibility. The optimized dosage of FEA-PCEI dressing could significantly accelerate wound healing with anti-infection ability, reduce the scar formation, and promote the hair follicle neogenesis. This study provided a wound-repairing strategy through regulating the phenotype of immune cells by the designing bioactive multifunctional biomaterials.
623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update
Authors: A.G. Omlin, J.N. Graff, C.J. Hoimes, S.T. Tagawa, C. Hwang, D. Kilari, A.J. Ten Tije, R. McDermott, U.N. Vaishampayan, T. Elliott, W.R. Gerritsen, H. Wu, J. Kim, C. Schloss, J.S. de Bono, E.S. Antonarakis
Journal: Annals of Oncology (2020)
1353P Clinical utility of circulating tumour (ct) DNA next generation sequencing (NGS) for target identification in diagnostic and acquired resistance settings in metastatic NSCLC (mNSCLC): Single centre experience
Authors: N. Tokaca, W. Cui, I. Faull, R.J. Nagy, S. Scott, N. Yousaf, S. Popat
Journal: Annals of Oncology (2020)
722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study
Authors: M. Gross-Goupil, A. Fléchon, L. Mourey, D. Topart, G. Gravis, S. Oudard, J.M. Tourani, L. Geoffrois, E. Meriaux, A. Thiery-Vuillemin, P. Barthélémy, S. Ladoire, B. Laguerre, R. Bourouina, V. Perrot, B. Escudier, L. Albiges
Journal: Annals of Oncology (2020)
704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
Authors: P. Grivas, S.H. Park, E. Voog, C. Caserta, B. Perez Valderrama, H. Gurney, H. Kalofonos, S. Radulovic, W. Demey, A. Ullén, Y. Loriot, S.S. Sridhar, N. Tsuchiya, E. Kopyltsov, S. Gupta, B. Huang, N. Costa, J.A. Blake-Haskins, A. di Pietro, T.B. Powles
Journal: Annals of Oncology (2020)
Changes in Health Care–Related Financial Burden for US Families With Children Associated With the Affordable Care Act
Authors: Lauren E. Wisk, Alon Peltz, Alison A. Galbraith
Journal: JAMA Pediatrics (2020)

<h3>Importance</h3> The Affordable Care Act (ACA) sought to improve access and affordability of health insurance. Although most ACA policies targeted childless adults, the extent to which these policies also impacted families with children remains unclear. <h3>Objective</h3> To examine changes in health care–related financial burden for US families with children before and after the ACA was implemented based on income eligibility for ACA policies. <h3>Design, Setting, and Participants</h3> Data used for this cohort study were obtained from the 2000-2017 Medical Expenditure Panel Survey, a nationally representative, population-based survey. Multivariable regression with a difference-in-differences estimator was used to examine changes in family financial burden before and after ACA implementation according to income-based ACA eligibility groups (≤138% [lowest-income], 139%-250% [low-income], 251%-400% [middle-income], and &gt;400% [high-income] federal poverty level). The cohort included 92 165 families with 1 or more children (age ≤18 years) and 1 or more adult parents/guardians. <h3>Exposures</h3> Income-based eligibility groups during post-ACA years (calendar years 2014-2017) vs pre-ACA years (calendar years 2000-2013). <h3>Main Outcomes and Measures</h3> Family annual out-of-pocket (OOP) health care and premium cost burden relative to income. High OOP burden was determined based on a previously validated algorithm with relative cost thresholds that vary across incomes, and extreme OOP burden was defined as costs exceeding 10% of income. Premiums exceeding 9.5% of income were classified as burdensome and premiums relative to median household income defined an unaffordability index. <h3>Results</h3> Compared with high-income families who experienced a lesser change post-ACA implementation (high OOP burden, 1.1% pre-ACA vs 0.9% post-ACA), the lowest-income families saw the greatest reduction in high OOP burden (35.6% pre-ACA vs 23.7% post-ACA; difference-in-differences: −11.4%; 95% CI, −13.2% to −9.5%) followed by low-income families (24.6% pre-ACA vs 17.3% post-ACA, difference-in-differences: −6.8%; 95% CI, −8.7% to −4.9%) and middle-income families (6.1% pre-ACA vs 4.6% post-ACA, difference-in-differences: −1.2%; 95% CI, −2.3% to −0.01%). Although premiums rose for all groups, premium unaffordability was the least exacerbated for the lowest-, low-, and middle-income families compared with higher-income families. <h3>Conclusions and Relevance</h3> The findings of this study suggest that low- and middle-income families with children who were eligible for ACA Medicaid expansions and Marketplace subsidies experienced greater reductions in health care–related financial burden after the ACA was implemented compared with families with higher incomes. However, despite ACA policies, many low- and middle-income families with children appear to continue to face considerable financial burden from premiums and OOP costs.
1427P A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction
Authors: Q. Zhao, J. Wang, H. Guo, Y. Li, C. Lin, Y. Cheng, Z. Zhang, D. Wang, X. Zhao, Y. Liu, S. Jing, P. Yang, Y. Tian, Y. Liu
Journal: Annals of Oncology (2020)
High‐Throughput Tumor‐on‐a‐Chip Platform to Study Tumor–Stroma Interactions and Drug Pharmacokinetics
Authors: Chun‐Wei Chi, Yeh‐Hsing Lao, A. H. Rezwanuddin Ahmed, Elizabeth C. Benoy, Chenghai Li, Zeynep Dereli‐Korkut, Bingmei M. Fu, Kam W. Leong, Sihong Wang
Journal: Advanced Healthcare Materials (2020)

Abstract Drug screening in oncology, especially for triple‐negative breast cancer (TNBC), has high demand but remains unsatisfactory. Currently available models are either nonrepresentative of the complex tumor microenvironment or only suitable for low throughput screening, resulting in a low‐yield success for drug development. To tackle these issues, the L‐ TumorChip system is developed in this study. It is a three‐layered microfluidic tumor‐on‐a‐chip platform integrating tumor microvasculature and tumor–stromal microenvironment with high throughput screening capability. Its layered and modular design is readily scalable through simple integration of multiple units. Here, L‐ TumorChip is validated with a TNBC model. The L ‐TumorChip system emulates certain tumor–stroma complexities and tumor–endothelium interactions, including TNBC invasion through the leaky microvasculature and angiogenesis. Additionally, with this L ‐TumorChip, the influence of different stromal cells, including normal fibroblasts, mesenchymal stem cells, and cancer‐associated fibroblasts (CAF), on cancer cell growth as well as the stromal effects on drug responses to doxorubicin treatment is investigated. The presence of CAF delays drug pharmacokinetics, while apoptotic responses indicated by caspase‐3 activities are higher in coculture with normal fibroblasts. Collectively, the L ‐TumorChip system represents a translational high‐throughput screening toolkit that enables drug screening with a scenario closer to the in vivo conditions. This potential use may therefore facilitate development of new cancer drugs.
Abstract 16565: Integration Of A Genome-wide Polygenic Score With ACC/AHA Pooled Cohorts Equation In Prediction Of Coronary Artery Disease Events In >285,000 Participants
Authors: George Hindy, Krishna Aragam, Mark Chaffin, Marju Orho-Melander, Olle Melander, Amit V Khera, Sekar Kathiresan
Journal: Circulation (2019)

Genome-wide polygenic scores for coronary artery disease (GPSCAD) integrate information from millions of common DNA polymorphisms into a single measure of inherited susceptibility. The incremental ...
Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress
Authors: Zhiyong Xiong, Changfei Yuan, Jian shi, Wei Xiong, Yu Huang, Wen Xiao, Hongmei Yang, Ke Chen, Xiaoping Zhang
Journal: Theranostics (2020)

Rationale: Tumors have significant abnormalities in various biological properties. In renal cell carcinoma (RCC), metabolic abnormalities are characteristic biological dysfunction that cannot be ignored. Despite this, many aspects of this dysfunction have not been fully explained. The purpose of this study was to reveal a new mechanism of metabolic and energy-related biological abnormalities in RCC. Methods: Molecular screening and bioinformatics analysis were performed in RCC based on data from The Cancer Genome Atlas (TCGA) database. Regulated pathways were investigated by qRT-PCR, immunoblot analysis and immunohistochemistry. A series of functional analyses was performed in cell lines and xenograft models. Results: By screening the biological abnormality core dataset-mitochondria-related dataset and the metabolic abnormality core dataset-energy metabolism-related dataset in public RCC databases, PCK2 was found to be differentially expressed in RCC compared with normal tissue. Further analysis by the TCGA database showed that PCK2 was significantly downregulated in RCC and predicted a poor prognosis. Through additional studies, it was found that a low expression of PCK2 in RCC was caused by methylation of its promoter region. Restoration of PCK2 expression in RCC cells repressed tumor progression and increased their sensitivity to sunitinib. Finally, mechanistic investigations indicated that PCK2 mediated the above processes by promoting endoplasmic reticulum stress. Conclusions: Collectively, our results identify a specific mechanism by which PCK2 suppresses the progression of renal cell carcinoma (RCC) and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress. This finding provides a new biomarker for RCC as well as novel targets and strategies for the treatment of RCC.
1667TiP A phase II, single arm study of avelumab in combination with axitinib in patients with unresectable/metastatic gastrointestinal stromal tumor after failure of standard therapy - AXAGIST
Authors: K. Kozak, M.A. Pantaleo, E. Fumagalli, M. Nannini, E. Bylina, J. Poleszczuk, A. Klimczak, P.G. Casali, P. Rutkowski
Journal: Annals of Oncology (2020)
Biased Mutation and Selection in RNA Viruses
Authors: Talia Kustin, Adi Stern
Journal: Molecular Biology and Evolution (2020)

Abstract RNA viruses are responsible for some of the worst pandemics known to mankind, including outbreaks of Influenza, Ebola, and COVID-19. One major challenge in tackling RNA viruses is the fact they are extremely genetically diverse. Nevertheless, they share common features that include their dependence on host cells for replication, and high mutation rates. We set out to search for shared evolutionary characteristics that may aid in gaining a broader understanding of RNA virus evolution, and constructed a phylogeny-based data set spanning thousands of sequences from diverse single-stranded RNA viruses of animals. Strikingly, we found that the vast majority of these viruses have a skewed nucleotide composition, manifested as adenine rich (A-rich) coding sequences. In order to test whether A-richness is driven by selection or by biased mutation processes, we harnessed the effects of incomplete purifying selection at the tips of virus phylogenies. Our results revealed consistent mutational biases toward U rather than A in genomes of all viruses. In +ssRNA viruses, we found that this bias is compensated by selection against U and selection for A, which leads to A-rich genomes. In −ssRNA viruses, the genomic mutational bias toward U on the negative strand manifests as A-rich coding sequences, on the positive strand. We investigated possible reasons for the advantage of A-rich sequences including weakened RNA secondary structures, codon usage bias, and selection for a particular amino acid composition, and conclude that host immune pressures may have led to similar biases in coding sequence composition across very divergent RNA viruses.
1267P Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
Authors: G. Gao, Y. Wang, S. Ren, J. Zhao, G. Chen, J. Chen, K. Gu, R. Guo, Y. Pan, Q. Wang, C. Zhou
Journal: Annals of Oncology (2020)